Shots:
- The P-III SELECT-COMPARE study evaluates the safety and efficacy of Rinvoq (15 mg, qd) vs PBO and Humira (SC, 40mg, every other week) in a ratio (2:2:1) in adult patients with a mod. to sev. active RA who had an inadequate response to MTX and continued a stable background of MTX
- The new analysis showed that the therapy maintained high rates of clinical remission & low disease activity compared with Humira @ 3yrs., the safety profile was consistent with previously reported and in P-III integrated safety analysis, no new safety risks identified up to 4.5yrs.
- Rinvoq is a selective & reversible JAK inhibitor, approved for three adult rheumatic indications in the EU
Click here to read full press release/ article | Ref: Abbvie | Image: Wall Street Journal
The post AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheumatoid Arthritis at EULAR 2021 first appeared on PharmaShots.
